Trials / Completed

CompletedNCT00147576

Study To Examine Effect Of CP-866,087 On Consumption And Craving Of Alcohol In Alcohol Dependent Subjects.

Randomized, Placebo-Controlled Parallel Group Study Comparing Effect Of Three Doses Of CP-866,087 And Naltrexone On Acute Alcohol Consumption And Craving After Seven Days Of Treatment In Alcohol Dependent (DSM IV) Subjects Who Are Not Currently Seeking Treatment

Status: Completed
Phase: Phase 2
Study type: Interventional
Enrollment: 88 (actual)

Sponsor: Pfizer · Industry
Sex: All
Age: 21 Years – 65 Years
Healthy volunteers: Not accepted

Summary

Test the hypothesis that increasing doses of CP-866,087 will decrease the total number of drinks consumed during a 2 hour acute alcohol consumption assessment and to determine the safety and tolerability of multiple doses of CP-866,087 in alcohol dependent subjects compared to placebo.

Conditions

Alcoholism

Interventions

Type	Name	Description
DRUG	CP-866,087

Timeline

Start date: 2003-12-01
Completion: 2004-12-01
First posted: 2005-09-07
Last updated: 2012-10-02

Locations

11 sites across 1 country: United States

Source: ClinicalTrials.gov record NCT00147576. Inclusion in this directory is not an endorsement.